Zydus Lifesciences rises on getting EIR for oncology injectable manufacturing facility in Ahmedabad
Zydus Lifesciences is currently trading at Rs. 1040.65, up by 3.65 points or 0.35% from its previous closing of Rs. 1037.00 on the BSE.
The scrip opened at Rs. 1039.75 and has touched a high and low of Rs. 1042.00 and Rs. 1033.75 respectively. So far 4804 shares were traded on the counter.
The BSE group 'A' stock of face value Rs. 1 has touched a 52 week high of Rs. 1087.80 on 30-Sep-2024 and a 52 week low of Rs. 797.05 on 07-Apr-2025.
Last one week high and low of the scrip stood at Rs. 1059.00 and Rs. 1025.30 respectively. The current market cap of the company is Rs. 104281.06 crore.
The promoters holding in the company stood at 74.99%, while Institutions and Non-Institutions held 18.26% and 6.74% respectively.
Zydus Lifesciences has received the Establishment Inspection Report (EIR) from the United States Food and Drug Administration (USFDA) for a GMP follow-up inspection conducted at its oncology injectable facility located at SEZ1, Ahmedabad from June 9 to June 18, 2025. The EIR has classified the facility as Voluntary Action Indicated (VAI).
The facility was earlier classified as an Official Action Indicated (OAI) in June 2024 which is now revised to Voluntary Action Indicated (VAI).
Zydus Lifesciences (formerly known as Cadila Healthcare), a company limited by shares, incorporated and domiciled in India, operates as an integrated pharmaceutical company with business encompassing the entire value chain in the research, development, production, marketing and distribution of pharmaceutical products.
